Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - mačky - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinárneho lieku je výlučne uvedená pri všetkých troch skupín sú zamerané na rovnaký čas.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

intervet international b.v. - fluralaner - ectoparaciticides, insekticídy a repelenty - kura - liečba napadnutia hydiny z červeného roztoča (dermanyssus gallinae) u nosníc, chovateľov a nosníc.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomektín, fipronil, praziquantel, (s) -metopren - antiparasitic products, insecticides and repellents, avermectins, eprinomectin, combinations, - mačky - pre mačky, ktoré sú alebo sú vystavené riziku zmiešaných napadnutí cestodami, nematódami a ektoparazitmi. veterinárneho lieku je výlučne uvedená pri všetkých troch skupín sú zamerané na rovnaký čas. ectoparasitestreatment a prevencia napadnutia tým, blchy (ctenocephalides felis). odstránenie blchy do 24 hodín. jedno ošetrenie bráni ďalšiemu škodcami najmenej jeden mesiac. prevencia environmentálnych velká znečistenia tým, že inhibuje vývoj velká nezrelé štádiách (vajíčka, larvy a pupae) viac ako mesiac. produkt sa môže použiť ako súčasť liečebnej stratégie na kontrolu alergickej dermatitídy (fad). liečba a prevencia napadnutia podľa kliešte (ixodes ricinus). odstránenie kliešťov do 48 hodín. jedno ošetrenie bráni ďalšiemu hmyzom až do 3 týždňov. liečba notoedric mange (notoedres cati). cestodestreatment z napadnutia s tapeworms (dipylidium caninum, taenia taeniaeformis, echinococcus multilocularis, joyeuxiella pasqualei (pre dospelých), a joyeuxiella fuhrmanni (pre dospelých)). nematodestreatment z napadnutia s gastrointestinálnymi háďatká (l3, l4 lariev a dospelých toxocara cati, dospelí toxascaris leonina, l4 lariev a dospelých ancylostoma tubaeforme a ancylostoma ceylanicum a dospelých ancylostoma brazilienze). liečba napadnutia s mačací lungworms (larvy l3, l4 lariev a dospelých aelurostrongylus abstrusus, l4 lariev a dospelých troglostrongylus brevior). liečba napadnutia s vesical červy (capillaria plica). prevencia heartworm ochorenia (dirofilaria immitis lariev) na jeden mesiac.

Slóvakía - slóvakíska - ŠÚKL (Štátny ústav pre kontrolu liečiv)

baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antineoplastické činidlá - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. u pacientov s egfr alebo alkalickÝm pozitívne nádor mutácie by tiež dostali cielenú liečbu pred prijatím keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

intervet international bv - indoxacarb, permethrin - permethrin, kombinácie, ectoparasiticides pre topické použitie, vrátane dph. insekticídy - psy - liečba velká hmyzom (ctenocephalides felis); výrobok má trvalé insekticídne účinnosť až 4 týždne pred ctenocephalides felis. produkt má perzistentnú akaricídnu účinnosť až 5 týždňov proti ixodes ricinus a až 3 týždne proti rhipicephalus sanguineus. jedna liečba poskytuje odpudzujúcu (anti-kŕmivú) aktivitu proti piesočkám (phlebotomus perniciosus) po dobu až 3 týždňov.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

elanco gmbh - pyriprol - ectoparasiticides pre topické použitie, vrátane dph. insekticídy - psy - liečba a prevencia zamorenia blchami (ctenocephalides canis a c. felis) u psov. Účinnosť proti novým napadnutím bleskom pretrváva minimálne 4 týždne. liečba a prevencia kliešť napadnutia (ixodes ricinus, rhipicephalus sanguineus, ixodes scapularis, dermacentor reticulatus, dermacentor variabilis, amblyomma americanum) v psov. Účinnosť proti kliešťom pretrváva počas 4 týždňov.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

pfizer limited  - metaflumizon - ectoparasiticides pre topické použitie, vrátane dph. insekticídy - mačky - liečba a prevencia infestácie blechami (ctenocephalides canis a c. felis) u mačiek. veterinárny liek môže byť použitý ako súčasť stratégie liečby blechy alergickej dermatitídy (fad).

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

zoetis belgium s.a. - moxidectin, sarolaner, pyrantel embonate - antiparasitics - psy - pre psov s, alebo na riziko, zmiešané vonkajších a vnútorných parazitov hmyzom. veterinárneho lieku je výlučne uviesť, kedy použiť proti kliešte alebo blchy a gastrointestinálne háďatká je uvedená v rovnakom čase. veterinárneho lieku poskytuje aj súbežné účinnosti prevencie heartworm choroby a angiostrongylosis. ectoparasitesfor liečbu kliešť hmyzom. veterinárny liek má okamžité a trvalé kliešť zabíjanie činnosti na 5 týždňov pred ixodes hexagonus, ixodes ricinus a rhipicephalus sanguineus a za 4 týždne pred dermacentor reticulatus;pre liečbu velká hmyzom (ctenocephalides felis a ctenocephalides canis). veterinárny liek má okamžité a trvalé velká zabíjanie aktivitu proti nové hmyzom na 5 týždňov;veterinárneho lieku môže byť použitý ako súčasť stratégie liečby na kontrolu velká alergie dermatitída (fad). gastrointestinálne nematodesfor liečbu gastrointestinálnych roundworm a hookworm infekcie:toxocara canis nezrelé dospelých (l5) a dospelých;ancylostoma caninum larvy l4, nezrelé dospelých (l5) a dospelých;toxascaris leonina dospelých;uncinaria stenocephala dospelých. iné nematodesfor prevenciu heartworm ochorenia (dirofilaria immitis);pre prevenciu angiostrongylosis znížením úrovne infekcie s nezrelé dospelých (l5) etapách angiostrongylus vasorum.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

eli lilly and company limited - spinosad, milbemycin oxime - antiparazitické prípravky, insekticídy a repelenty, endectocides - psy - na liečbu a prevenciu flea (ctenocephalides felis) škodcami v psov, kde jeden alebo viac z nasledujúcich označení sú povinné súčasne: prevencia heartworm ochorenia (l3, l4 dirofilaria immitis);prevencia angiostrongylosis znížením úrovne infekcie s nezrelé dospelých (l5) angiostrongylus vasorum, liečba gastrointestinálnych borovicové infekcie spôsobené hookworm (l4, nezrelé dospelých, l5) a dospelých ancylostoma caninum), roundworms (nezrelé dospelých l5 a dospelých toxocara canis a dospelých toxascaris leonina) a whipworm (pre dospelých trichuris vulpis).